<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20101204005305N22</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-11-10</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>The comparison of platelet-rich-fibrin impregnated alloderm Vs free gingival grafts Vs Alloderm to increase keratinized gingival width around dental implants</public_title>
      <acronym></acronym>
      <scientific_title>The comparison of Alloderm with platelet rich fibrin(PRF) Vs free gingival grafts Vs Alloderm  to increase the width of keratinized tissue around dental implants : a randomised controlled trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-12-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/80007</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization of patients is done by block randomized method, which is as follows: 3 sequences of 12 letters A’B’C are produced and people are entered into the study in groups of 12, then each sequence is removed from its envelope and people Based on it, they are assigned to study groups, Blinding description: The need to increase the width of the attached gingiva in these people was determined by a periodontist who does not know the type of treatment. A clinician that is blind to the study will perform all measurements. Patients in all groups receive surgery, but they are not informed about the surgical technique that is performed. However, care and complications after surgery are comprehensively explained.</study_design>
      <phase>N/A</phase>
      <hc_freetext>width of keratinized tissue around dental implants.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 1- First, ten milliliters of whole venous blood will be collected in two sterile PRF preparation tubes of ten milliliters.2- The tubes will be inserted into the centrifuge at a speed of 700 rpm for 3 minutes.3- Blood is divided into three layers. A cell-free plasma, a middle section containing a fibrin clot, and a red section containing red blood cells at the bottom of the tube.4- PRF is drawn with a syringe.5- Then Eloderm is prepared in the same way as described in the previous group6- Now Alloderm with PRF will be mixed and fixed with periosteal sutures using 0-5 non-absorbable nylon suture material on the recipient site. Intervention 2: Intervention group:In the ADM group, the acellular dermal matrix (AlloDerm®) will be prepared and applied according to the manufacturer's instructions. In summary:1- The membrane will be hydrated with 50 ml of sterile saline solution for 5 minutes.2- When the protective backing paper is removed, the ADM substance will be transferred to another container containing 50 ml of sterile serum solution and will be left there for 5 minutes.3- Then, the allograft will be cut to a size of one by two centimeters4- It will be fixed on the recipient site with periosteal sutures using 0-5 non-absorbable nylon suture material. Intervention 3: Control group:For the control group:1. Taking a 1 to 2 mm thick FGG from the palate, depending on the amount of tissue in the palate of each patient and with dimensions of 1 x 1.5 cm2. Placement and fixation of FGG on the recipient surface with crossed sutures and non-absorbable sutures (Nylon 5.0, Ethilon®).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>mohammad mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>shafa street Dental School</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618759689</zip>
        <telephone>+98 34 3211 9021</telephone>
        <email>mmohammadi28@yahoo.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Mohammad Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Periodontics Department, Kerman Dental School, Shafa Street</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618759689</zip>
        <telephone>+98 34 3211 9021</telephone>
        <email>mmohammadi28@yahoo.com</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>less than 2mm keratinized gingiva
healthy periimplant tissue
plaque index and bleeding index less than 20%
good overal health</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>smokers(more than 10 cigarettes per day)
Patients with systemic diseases that can interfere with recovery.
Patients treated with bisphosphonates and patients who have previously received jaw radiotherapy.
Patients with moderate to severe periodontitis.
Pregnant women and nursing mothers.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
      <i_code>Treatment - Surgery</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 1- First, ten milliliters of whole venous blood will be collected in two sterile PRF preparation tubes of ten milliliters.2- The tubes will be inserted into the centrifuge at a speed of 700 rpm for 3 minutes.3- Blood is divided into three layers. A cell-free plasma, a middle section containing a fibrin clot, and a red section containing red blood cells at the bottom of the tube.4- PRF is drawn with a syringe.5- Then Eloderm is prepared in the same way as described in the previous group6- Now Alloderm with PRF will be mixed and fixed with periosteal sutures using 0-5 non-absorbable nylon suture material on the recipient site.</i_keyword>
      <i_keyword>Intervention group:In the ADM group, the acellular dermal matrix (AlloDerm®) will be prepared and applied according to the manufacturer's instructions. In summary:1- The membrane will be hydrated with 50 ml of sterile saline solution for 5 minutes.2- When the protective backing paper is removed, the ADM substance will be transferred to another container containing 50 ml of sterile serum solution and will be left there for 5 minutes.3- Then, the allograft will be cut to a size of one by two centimeters4- It will be fixed on the recipient site with periosteal sutures using 0-5 non-absorbable nylon suture material.</i_keyword>
      <i_keyword>Control group:For the control group:1. Taking a 1 to 2 mm thick FGG from the palate, depending on the amount of tissue in the palate of each patient and with dimensions of 1 x 1.5 cm2. Placement and fixation of FGG on the recipient surface with crossed sutures and non-absorbable sutures (Nylon 5.0, Ethilon®).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Width of keratinized tissue around dental implants. Timepoint: Keratinized gingival width is achieved in patients  3 months after surgery. Method of measurement: A periodontal probe is used to measure the distance between the gingival margin and the mucogingival junction.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The depth of the vestibule. Timepoint: 3 months after surgery. Method of measurement: The distance from the gingival margin to the deepest part of the vestibule.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-09-08</approval_date>
        <contact_name>Ethics Committee of Kerman Medical Sciences</contact_name>
        <contact_address>shafa street dental school Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
